Sun Pharmaceutical Industries Limited, a leader in the pharmaceutical sector, is dedicated to enhancing patient care in areas such as psoriasis, alopecia areata, and acne. At the 2026 AAD Annual Meeting held in Denver, Colorado, the company presented 14 abstracts, showcasing its commitment to advancing dermatology and immunology.

Among the highlights was ILUMYA, a drug aimed at treating moderate-to-severe plaque psoriasis and nail psoriasis. The presentation emphasized not only the clinical efficacy and safety of ILUMYA but also its performance over time in real-world settings.

Another significant development is LEQSELVI, which is utilized for the treatment of severe alopecia areata. This therapy represents a crucial advancement for patients struggling with this challenging condition.

Additionally, WINLEVI, indicated for acne vulgaris, was discussed in the context of combination therapies, showcasing its versatility in dermatological treatment.

However, not all news was positive. The Phase II FLASH study for Fibromun did not meet its primary endpoint for progression-free survival (PFS), raising questions about its future in the market.

On a brighter note, Nidlegy achieved a remarkable milestone, with complete pathological responses in 52.6% of patients in the Phase II ‘Duncan’ study. This achievement underscores the potential of Nidlegy in treating specific patient populations.

Furthermore, the GLIOSTELLA study in late-line glioblastoma has completed enrollment in the U.S., marking a significant step forward in research for this aggressive cancer.

In light of previous challenges, a new submission for Nidlegy is being prepared after the withdrawal of a prior Marketing Authorization Application in 2025. This proactive approach reflects Sun Pharma’s resilience and commitment to bringing innovative therapies to market.

Dr. Ahmad Naim, a key figure at Sun Pharma, stated, “The data we are presenting at AAD underscore our commitment to advancing dermatology and immunology through meaningful science – spanning not only clinical efficacy and safety, but also how these therapies perform over time and in real-world practice.”

As the industry watches closely, observers expect that these developments will pave the way for further advancements in dermatological treatments, enhancing patient care and outcomes in the years to come.

The post Sun Pharma Unveils Promising Developments at AAD Annual Meeting appeared first on The Business News.

What does the recent decline in IOL Chemicals & Pharmaceuticals Ltd’s stock price signify for investors? As of March 24, 2026, the stock closed at ₹71.60, marking a decline of 3.58% from the previous close of ₹74.26. This drop raises concerns about the company’s market position and future growth prospects.

The stock has experienced a tumultuous year, with a 52-week high of ₹126.60 and a low of ₹57.51, indicating significant volatility. The intraday trading range on the latest session was between ₹71.20 and ₹74.91, suggesting a lack of stability as investors react to market conditions.

Technical indicators paint a bearish picture for IOL Chemicals. The Moving Average Convergence Divergence (MACD) remains bearish on both weekly and monthly timeframes, signaling potential further declines. Additionally, the Relative Strength Index (RSI) readings are neutral, providing no clear signals for traders looking to make informed decisions.

Further compounding the situation, the Bollinger Bands on both weekly and monthly charts are also bearish, with the stock price trending near the lower band. This technical analysis suggests that the stock may continue to face downward pressure unless significant changes occur.

In a recent move, MarketsMOJO downgraded IOL Chemicals & Pharmaceuticals Ltd from a Hold to a Sell rating as of January 5, 2026. The Mojo Score, which stands at 37.0, categorizes the stock as a Sell, reflecting a small-cap market cap grade that may deter potential investors.

Despite these challenges, the stock has shown some resilience, with a 4.54% gain over the past week. However, this is overshadowed by a 1.96% decline over the past month and a staggering 12.95% year-to-date decline. In contrast, the stock has managed a 9.98% return over the past year, which may provide a glimmer of hope for long-term investors.

The mixed returns of IOL Chemicals compared to the benchmark Sensex highlight the uncertainty surrounding its future. As investors weigh their options, the company’s ability to navigate these turbulent waters will be crucial in determining its market trajectory.

Looking ahead, the path for IOL Chemicals remains fraught with challenges. Investors and analysts alike will be keenly observing upcoming financial reports and market trends to gauge whether the company can recover from its current slump. Details remain unconfirmed regarding any strategic changes that may be in the pipeline, leaving many questions unanswered.

The post IOL Chemicals & Pharmaceuticals Ltd: A Deep Dive into Recent Market Movements appeared first on The Business News.

“The index rose 0.97% to 52,017, with gains broadening through the session as cash market liquidity improved,” noted a market analyst, reflecting on the Nikkei 225’s recent performance.

After a tumultuous two-day slide that saw the index drop over 3,700 points, the Nikkei 225 has made a notable recovery, closing up 501 points on Tuesday. This rebound was largely driven by significant gains in the pharmaceutical and metals sectors.

Leading the charge were Sumitomo Dainippon, which surged by 6.70%, Astellas Pharma, up 5.46%, and Sumitomo Metal Mining, which rose by 5.18%. These companies have been pivotal in lifting the index from its recent lows.

However, not all stocks shared in the recovery. Nintendo Co emerged as one of the weakest performers, experiencing a decline of 4.12%. This divergence highlights the ongoing volatility within the market.

The backdrop of this fluctuation is a weaker yen, currently hovering near 160 against the dollar. “A weaker yen tends to lift exporters’ reported revenues and margins, which can support indices,” explained another analyst, emphasizing the currency’s impact on market dynamics.

Japan’s government has also issued warnings regarding potential interventions in the foreign exchange market to combat disorderly moves, adding another layer of complexity to the current economic landscape.

Despite the positive movement in the Nikkei 225, analysts caution that volatility remains elevated. “The market continues to be very noisy and difficult, but I think at this point in time you need to be very cautious about getting overly aggressive with any position size in any index around the world,” one expert advised.

As investors navigate this turbulent environment, the focus will likely remain on the performance of key sectors and the broader implications of currency fluctuations on the Japanese economy.

With the Nikkei 225’s recent rebound, market participants will be keenly watching for further developments, particularly in the pharmaceutical and metals sectors, which have shown resilience amid the uncertainty.

Details remain unconfirmed.

The post Nikkei 225 Rebounds as Pharma and Metals Lead the Charge appeared first on The Business News.

“The index rose 0.97% to 52,017, with gains broadening through the session as cash market liquidity improved,” noted market analysts as the Nikkei 225 rebounded from a two-day slide that saw it lose over 3,700 points.

Leading the charge were key players in the pharmaceutical and metals sectors. Sumitomo Dainippon surged by 6.70%, while Astellas Pharma and Sumitomo Metal Mining followed closely with increases of 5.46% and 5.18%, respectively. These gains reflect a broader recovery in a market that has been shaken by recent volatility.

However, not all stocks shared in the upward momentum. Nintendo Co emerged as one of the weakest performers, suffering a decline of 4.12%. This mixed performance underscores the ongoing uncertainty in the market.

Market dynamics have been influenced by a weaker yen, which was hovering around 160 against the dollar. “A weaker yen tends to lift exporters’ reported revenues and margins, which can support indices,” analysts explained, highlighting the currency’s impact on Japan’s export-driven economy.

Japan’s government has also been vocal about its concerns regarding the currency’s fluctuations, warning that it may take action against disorderly foreign exchange moves. This statement reflects the delicate balance policymakers must maintain amid rising market volatility.

Despite the positive close, with the Nikkei 225 up 501 points on Tuesday, the overall market sentiment remains cautious. “The market continues to be very noisy and difficult, but I think at this point in time you need to be very cautious about getting overly aggressive with any position size in any index around the world,” one analyst cautioned.

Investors are closely monitoring these developments, as the interplay between currency movements and stock performance will be crucial in the coming days. The volatility in the Nikkei 225 is a reminder of the broader challenges faced by global markets.

As the situation evolves, market participants will be looking for signs of stability and potential opportunities amidst the fluctuations. The Nikkei 225’s recent performance may provide a glimmer of hope, but uncertainties remain, and details remain unconfirmed.

The post Nikkei 225 Rebounds with Strong Gains in Pharma and Metals Sectors appeared first on The Business News.

A counterfeit drug network was busted across five states in India on September 1, 2025, with significant developments in Lajpat Nagar, Delhi. The police laid a trap to catch a courier delivering a package containing Tramadol premix, leading to the arrest of Anirudh Rai.

The operation revealed a complex supply chain linking suppliers in Uttarakhand to traders in Delhi and a manufacturer in Bihar. Among those implicated was Tanishq Jha, whose factory in Patna was reportedly producing counterfeit medicines after its license had expired.

Police seized counterfeit medicines and psychotropic drugs valued at nearly Rs 50 crore during the operation. This included 20 kilograms of Tramadol premix stored in a warehouse in Roorkee by Amit, who is also under investigation.

Prashant, another key figure, acted as an intermediary connecting suppliers to buyers across North India. The police’s swift action has raised concerns about the scale of counterfeit drug production in the region.

A senior Crime Branch officer stated, “The goal was to trace the supply chain behind the material.” This investigation highlights the intricate web of suppliers, brokers, and manufacturers involved in the counterfeit drug trade.

Further insights from a Crime Branch officer noted, “When factories shut down or excess stock remains in the warehouses, middlemen sometimes try to move the material quickly.” This practice underscores the urgency with which these illegal operations are conducted.

Details about the profits shared between intermediaries and traders have also emerged, with an officer close to the investigation explaining, “The profits would then be shared between him and the trader who had sourced the material.” This indicates a well-organized network operating across multiple states.

The pharmaceutical belt around Roorkee has many small manufacturers that emerged after Uttarakhand was carved out of Uttar Pradesh, contributing to the prevalence of such illegal activities.

As the investigation continues, authorities are expected to delve deeper into the operations of Tanishq Jha and others involved, aiming to dismantle the entire network.

Details remain unconfirmed regarding the full extent of the network and any additional arrests that may follow.

The post Tanishq: Counterfeit Drug Network Involving Jha Busted in Delhi appeared first on The Business News.